Wells Fargo Maintains Overweight Rating on Phreesia (PHR)

Phreesia, Inc. (NYSE:PHR) is one of the 8 Healthcare Stocks Insiders Are Buying. On April 5, 2026, Wells Fargo lowered the price target on Phreesia, Inc. (NYSE:PHR) to $15 from $25 and maintained an Overweight rating. Wells Fargo said fiscal 2027 revenue guidance “decelerated sharply,” largely driven by the Network segment, citing valuation compression and slower growth, while noting recent Network channel checks were constructive.

On April 1, 2026, Citizens downgraded Phreesia to Market Perform from Outperform without a price target. Citizens said the updated fiscal 2027 revenue outlook was disappointing and raised concerns around the company’s ecosystem thesis, noting growth appears to be “sputtering out” in its largest subscription and related services segment.

20 Countries with the Most Expensive Healthcare in the World

On March 30, 2026, Phreesia reported Q4 adjusted EBITDA of $29.4M compared to $16.4M last year, with revenue of $127.1M versus the $126.6M consensus estimate. CEO Chaim Indig said the company achieved “critical financial milestones,” including positive GAAP net income of $2.3M and exceeding $100M in adjusted EBITDA and $50M in free cash flow for fiscal 2026.

Phreesia, Inc. (NYSE:PHR) provides SaaS-based software and payment solutions for the healthcare industry.

While we acknowledge the risk and potential of PHR as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than PHR and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.